Chapter 6 Disruption of Heme Synthesis by Polyhalogenated Aromatics

Advances in Molecular Toxicology

Volumn 3, Issue C, 2009, Pages 161-210

  Smith, Andrew G ^a   Chernova, Tatyana ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 2,3,7,8 TETRACHLORODIBENZOFURAN; 3,3',4,4',5 PENTACHLOROBIPHENYL; 3,3',4,4',5,5' HEXABROMOBIPHENYL; 5 AMINOLEVULINATE SYNTHASE; AMINOLEVULINIC ACID; AROMATIC HYDROCARBON RECEPTOR; BIPHENYL DERIVATIVE; BROMOBENZENE; COBALT; CYTOCHROME P450 1A2; DIBENZOFURAN DERIVATIVE; FERROCHELATASE; HEME; HEME OXYGENASE; HERBICIDE; HEXABROMOBENZENE; HEXACHLOROBENZENE; IRON; LEAD; POLYCHLORINATED BIPHENYL DERIVATIVE; PORPHOBILINOGEN; PORPHOBILINOGEN SYNTHASE; PORPHYRIN; PORPHYRINOGEN; PROTOPORPHYRIN; PROTOPORPHYRINOGEN OXIDASE; UNCLASSIFIED DRUG; UROPORPHYRIN; UROPORPHYRINOGEN; UROPORPHYRINOGEN DECARBOXYLASE;

AROMATIC HYDROCARBON RECEPTOR GENE; CHEMICAL STRUCTURE; CLINICAL FEATURE; CYP1A2 GENE; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; GENE; GENE MUTATION; GENETIC PREDISPOSITION; HEME SYNTHESIS; HEMOCHROMATOSIS GENE; HEPATIC PORPHYRIA; HUMAN; INCIDENCE; IRON METABOLISM; LIVER CARCINOGENESIS; LIVER INJURY; LIVER LEVEL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE TRAIT LOCUS; REVIEW;

EID: 76449106419     PISSN: 18720854     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1872-0854(09)00006-X     Document Type: Review

References (260)

1. Furuyama K., Kaneko K., and Vargas P.D. Heme as a magnificent molecule with multiple missions: Heme determines its own fate and governs cellular homeostasis. Tohoku J. Exp. Med. 213 (2007) 1-16
2. Ajioka R.S., Phillips J.D., and Kushner J.P. Biosynthesis of heme in mammals. Biochim. Biophys. Acta 1763 (2006) 723-736
3. Anderson K.E., Sassa S., Bishop D.F., and Desnick R.J. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver C.R., Beaudet A.R., Sly W., Valle D., Vogelstein B., and Childs B. (Eds). The Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill, New York 2991-3062
4. Tsiftsoglou A.S., Tsamadou A.I., and Papadopoulou L.C. Heme as key regulator of major mammalian cellular functions: Molecular, cellular, and pharmacological aspects. Pharmacol. Ther. 111 (2006) 327-345
5. Boehning D., and Snyder S.H. Novel neural modulators. Annu. Rev. Neurosci. 26 (2003) 105-131
6. Kumar S., and Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol. Lett. 157 (2005) 175-188
7. Pamplona A., Ferreira A., Balla J., Jeney V., Balla G., Epiphanio S., Chora A., Rodrigues C.D., Gregoire I.P., Cunha-Rodrigues M., Portugal S., Soares M.P., et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat. Med. 13 (2007) 703-710
8. Takahashi T., Shimizu H., Morimatsu H., Inoue K., Akagi R., Morita K., and Sassa S. Heme oxygenase-1: A fundamental guardian against oxidative tissue injuries in acute inflammation. Mini-Rev. Med. Chem. 7 (2007) 745-753
9. Sassa S., and Nagai T. The role of heme in gene expression. Int. J. Hematol. 63 (1996) 167-178
10. Hou S., Reynolds M.F., Horrigan F.T., Heinemann S.H., and Hoshi T. Reversible binding of heme to proteins in cellular signal transduction. Acc. Chem. Res. 39 (2006) 918-924
11. Gilles-Gonzalez M.A., and Gonzalez G. Heme-based sensors: defining characteristics, recent developments, and regulatory hypotheses. J. Inorg. Biochem. 99 (2005) 1-22
12. Dioum E.M., Rutter J., Tuckerman J.R., Gonzalez G., Gilles-Gonzalez M.A., and McKnight S.L. NPAS2: A gas-responsive transcription factor. Science 298 (2002) 2385-2387
13. Kaasik K., and Lee C.C. Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. Nature 430 (2004) 467-471
14. Raghuram S., Stayrook K.R., Huang P., Rogers P.M., Nosie A.K., McClure D.B., Burris L.L., Khorasanizadeh S., Burris T.P., and Rastinejad F. Identification of heme as the ligand for the orphan nuclear receptors REV-erbalpha and REV-erbbeta. Nat. Struct. Mol. Biol. 14 (2007) 1207-1213
15. Yin L., Wu N., Curtin J.C., Qatanani M., Szwergold N.R., Reid R.A., Waitt G.M., Parks D.J., Pearce K.H., Wisely G.B., and Lazar M.A. Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science 318 (2007) 1786-1789
16. Faller M., Matsunaga M., Yin S., Loo J.A., and Guo F. Heme is involved in microRNA processing. Nat. Struct. Mol. Biol. 14 (2007) 23-29
17. Hu R.G., Wang H., Xia Z., and Varshavsky A. The N-end rule pathway is a sensor of heme. Proc. Natl. Acad. Sci. USA 105 (2008) 76-81
18. Tang X.D., Xu R., Reynolds M.F., Garcia M.L., Heinemann S.H., and Hoshi T. Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels. Nature 425 (2003) 531-535
19. Chernova T., Nicotera P., and Smith A.G. Heme deficiency is associated with senescence and causes suppression of N-methyl-d-aspartate receptor subunits expression in primary cortical neurons. Mol. Pharmacol. 69 (2006) 697-705
20. Chernova T., Steinert J.R., Guerin C.J., Nicotera P., Forsythe I.D., and Smith A.G. Neurite degeneration induced by heme deficiency mediated via inhibition of NMDA receptor-dependent extracellular signal-regulated kinase 1/2 activation. J. Neurosci. 27 (2007) 8475-8485
21. De Matteis F. Toxicological aspects of liver heme biosynthesis. Semin. Hematol. 25 (1988) 321-329
22. De Matteis F., and Stonard M. Experimental porphyrias as models for human hepatic porphyrias. Semin. Hematol. 14 (1977) 187-192
23. Hamilton J.W., Bement W.J., Sinclair P.R., Sinclair J.F., Alcedo J.A., and Wetterhahn K.E. Heme regulates hepatic 5-aminolevulinate synthase mRNA expression by decreasing mrna half-life and not by altering its rate of transcription. Arch. Biochem. Biophys. 289 (1991) 387-392
24. Kolluri S., Sadlon T.J., May B.K., and Bonkovsky H.L. Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem. J. 392 (2005) 173-180
25. Srivastava G., Borthwick I.A., Maguire D.J., Elferink C.J., Bawden M.J., Mercer J.F., and May B.K. Regulation of 5-aminolevulinate synthase mRNA in different rat tissues. J. Biol. Chem. 263 (1988) 5202-5209
26. Yamamoto M., Kure S., Engel J.D., and Hiraga K. Structure, turnover, and heme-mediated suppression of the level of mRNA encoding rat liver delta-aminolevulinate synthase. J. Biol. Chem. 263 (1988) 15973-15979
27. Dailey T.A., Woodruff J.H., and Dailey H.A. Examination of mitochondrial protein targeting of haem synthetic enzymes: In vivo identification of three functional haem-responsive motifs in 5-aminolaevulinate synthase. Biochem. J. 386 (2005) 381-386
28. Fraser D.J., Zumsteg A., and Meyer U.A. Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J. Biol. Chem. 278 (2003) 39392-39401
29. Guberman A.S., Scassa M.E., Giono L.E., Varone C.L., and Canepa E.T. Inhibitory effect of AP-1 complex on 5-aminolevulinate synthase gene expression through sequestration of camp-response element protein (CRE)-binding protein (CBP) coactivator. J. Biol. Chem. 278 (2003) 2317-2326
30. Handschin C., and Meyer U.A. Induction of drug metabolism: The role of nuclear receptors. Pharmacol. Rev. 55 (2003) 649-673
31. Scassa M.E., Guberman A.S., Varone C.L., and Canepa E.T. Phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase signaling pathways are required for the regulation of 5-aminolevulinate synthase gene expression by insulin. Exp. Cell Res. 271 (2001) 201-213
32. Jackson A.H., Sancovich H.A., Ferramola A.M., Evans N., Games D.E., Matlin S.A., Elder G.H., and Smith S.G. Macrocyclic intermediates in the biosynthesis of porphyrins. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 273 (1976) 191-206
33. Smith A.G., and Francis J.E. Investigations of rat liver uroporphyrinogen decarboxylase. Comparisons of porphyrinogens I and III as substrates and the inhibition by porphyrins. Biochem. J. 195 (1981) 241-250
34. Phillips J.D., Whitby F.G., Kushner J.P., and Hill C.P. Characterization and crystallization of human uroporphyrinogen decarboxylase. Protein Sci. 6 (1997) 1343-1346
35. Luo J., and Lim C.K. Order of uroporphyrinogen III decarboxylation on incubation of porphobilinogen and uroporphyrinogen III with erythrocyte uroporphyrinogen decarboxylase. Biochem. J. 289 (1993) 529-532
36. Smith A.G., and De Matteis F. Oxidative injury mediated by the hepatic cytochrome P-450 system in conjunction with cellular iron. Effects on the pathway of haem biosynthesis. Xenobiotica 20 (1990) 865-877
37. Jeney V., Balla J., Yachie A., Varga Z., Vercellotti G.M., Eaton J.W., and Balla G. Pro-oxidant and cytotoxic effects of circulating heme. Blood 100 (2002) 879-887
38. Sassa S. Why heme needs to be degraded to iron, biliverdin IX alpha, and carbon monoxide?. Antioxid. Redox Signal. 6 (2004) 819-824
39. Wagener F.A., Volk H.D., Willis D., Abraham N.G., Soares M.P., Adema G.J., and Figdor C.G. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol. Rev. 55 (2003) 551-571
40. Sassa S., and Kappas A. Molecular aspects of the inherited porphyrias. J. Intern. Med. 247 (2000) 169-178
41. Badminton M.N., and Elder G.H. Molecular mechanisms of dominant expression in porphyria. J. Inherit. Metab. Dis. 28 (2005) 277-286
42. Meissner P.N., Dailey T.A., Hift R.J., Ziman M., Corrigall A.V., Roberts A.G., Meissner D.M., Kirsch R.E., and Dailey H.A. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat. Genet. 13 (1996) 95-97
43. Elder G.H. Porphyria cutanea tarda. Semin. Liver Dis. 18 (1998) 67-75
44. Elder G.H. Porphyria cutanea tarda and related disorders. In: Kadish K.M., Smith K.M., and Guilard R. (Eds). Medical Aspects of Porphyrins. Porphyrin Handbook 14 (2003), Academic Press, San Diego 67-92
45. Egger N.G., Goeger D.E., Payne D.A., Miskovsky E.P., Weinman S.A., and Anderson K.E. Porphyria cutanea tarda: Multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig. Dis. Sci. 47 (2002) 419-426
46. Smith A.G. Porphyria caused by chlorinated AH receptor ligands and associated mechanisms of liver injury and cancer. In: Kadish K.M., Smith K.M., and Guilard R. (Eds). Medical Apects of Porphyrins, Porphyrin Handbook 14 (2003), Academic Press, San Diego 169-210
47. Elder G.H., Urquhart A.J., De Salamanca R.E., Munoz J.J., and Bonkovsky H.L. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 2 (1985) 229-233
48. Bulaj Z.J., Phillips J.D., Ajioka R.S., Franklin M.R., Griffen L.M., Guinee D.J., Edwards C.Q., and Kushner J.P. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95 (2000) 1565-1571
49. Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., and Elder G.H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 349 (1997) 321-323
50. Maines M.D. Enzymatic basis of metal ion alterations of cellular heme and glutathione metabolism. Fundam. Appl. Toxicol. 1 (1981) 358-367
51. Claudio L., Lee T., Wolff M.S., and Wetmur J.G. A murine model of genetic susceptibility to lead bioaccumulation. Fundam. Appl. Toxicol. 35 (1997) 84-90
52. Tschudy D.P., Hess R.A., and Frykholm B.C. Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid. J. Biol. Chem. 256 (1981) 9915-9923
53. Lim C.E., Matthaei K.I., Blackburn A.C., Davis R.P., Dahlstrom J.E., Koina M.E., Anders M.W., and Board P.G. Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am. J. Pathol. 165 (2004) 679-693
54. Sinclair P.R., Gorman N., Walton H.S., Sinclair J.F., Jacobs J.M., and Jacobs N.J. Protoporphyrinogen accumulation in cultured hepatocytes treated with the diphenyl ether herbicide, acifluorfen. Cell. Mol. Biol. (Noisy-le-grand) 40 (1994) 891-897
55. Fowler B.A., Conner E.A., and Yamauchi H. Metabolomic and proteomic biomarkers for III-V semiconductors: chemical-specific porphyrinurias and proteinurias. Toxicol. Appl. Pharmacol. 206 (2005) 121-130
56. Woods J.S., Echeverria D., Heyer N.J., Simmonds P.L., Wilkerson J., and Farin F.M. The association between genetic polymorphisms of coproporphyrinogen oxidase and an atypical porphyrinogenic response to mercury exposure in humans. Toxicol. Appl. Pharmacol. 206 (2005) 113-120
57. Sinclair P., Gibbs A.H., Sinclair J.F., and De Matteis F. Formation of cobalt protoporphyrin in the liver of rats. A mechanism for the inhibition of liver haem biosynthesis by inorganic cobalt. Biochem. J. 178 (1979) 529-538
58. De Matteis F., and Marks G.S. Cytochrome P450 and its interactions with the heme biosynthetic pathway. Can. J. Physiol. Pharmacol. 74 (1996) 1-8
59. Davies R., Schuurman A., Barker C.R., Clothier B., Chernova T., Higginson F.M., Judah D.J., Dinsdale D., Edwards R.E., Greaves P., Gant T.W., and Smith A.G. Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. Am. J. Pathol. 166 (2005) 1041-1053
60. Elder G.H. Porphyria caused by hexachlorobenzene and other polyhalogenated aromatic hydrocarbons. In: De Matteis F., and Aldridge W.N. (Eds). Heme and Hemo-proteins (1978), Springer-Verlag, Berlin 157-200
61. Cam C. A new epidemic dermatosis of children. Ann. Dermatol. Syphiligr. (Paris) 87 (1960) 393-397
62. Cam C., and Nigogosyan G. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. J. Am. Med. Ass. 183 (1963) 88-91
63. Cetingil A.I., and Ozen M.A. Toxic porphyria. Blood 16 (1960) 1002-1011
64. Dogramaci I. Porphyrias and porphyrin metabolism, with special reference to porphyria in childhood. Adv. Pediatr. 13 (1964) 11-63
65. Schmid R. Cutaneous porphyria in Turkey. N. Engl. J. Med. 263 (1960) 397-398
66. Kantemir I., Cam C., and Kayaalp O. Investigations and observations on two diseases: Kara Yara and Pembe Yara which are observed in the South-East part of Turkey. Turk. Bull. Hyg. Exp. Biol. 20 (1960) 79-83
67. Dogramaci I., Wray J.D., Ergene T., Sezer V., and Muftu Y. Porphyria turcica, a survey of 592 cases of cutaneous porphyria seen in southeastern Turkey. Turk. J. Pediatr. 4 (1962) 138-147
68. Dogramaci I., Kenanoglu A., Muftu Y., Ergene T., and Wray J.D. Bone and joint changes in patients with porphyria turcica. Turk. J. Pediatr. 4 (1962) 149-156
69. Dogramaci I., Tinaztepe B., and Gunalp A. Condition of the liver in patients with toxic cutaneous porphyria. Turk. J. Pediatr. 4 (1962) 103-106
70. Dogramaci I., Duzgunes O., Ergene T., and Gocmen A. A possible genetic factor in the etiology of porphyria Turcica. Turk. J. Pediatr. 4 (1962) 193-200
71. Gocmen A., Peters H.A., Cripps D.J., Bryan G.T., and Morris C.R. Hexachlorobenzene episode in Turkey. Biomed. Environ. Sci. 2 (1989) 36-43
72. Peters H.A., Gocmen A., Cripps D.J., and Bryan G.T. Epidemiology of hexachlorobenzene-induced porphyria in Turkey-clinical and laboratory. Neurology 31 (1981) 111 111
73. Morley A., Geary D., and Harben F. Hexachlorobenzene pesticides and porphyria. Med. J. Aust. 1 (1973) 565
74. Selden A.I., Bodin L.S., Westberg H., and Thunell S. Porphyrin status in aluminium foundry workers exposed to hexachlorobenzne and octachlorostyrene. Arch. Environ. Health 54 (1999) 248-253
75. Sunyer J., Herrero C., Ozalla D., Sala M., Ribas-Fito N., Grimalt J., and Basagana X. Serum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene. Environ. Health 1 (2002) 1
76. Daniell W.E., Stockbridge H.L., Labbe R.F., Woods J.S., Anderson K.E., Bissell D.M., Bloomer J.R., Ellefson R.D., Moore M.R., Pierach C.A., Schreiber W.E., Tefferi A., et al. Environmental chemical exposures and disturbances of heme synthesis. Environ. Health Perspect. 105 Suppl. 1 (1997) 37-53
77. Enriquez de Salamanca R., Lopez-Miras A., Munoz J.J., To-Figueras J., and Conde C. Is hexachlorobenzene human overload related to porphyria cutanea tarda? A speculative hypothesis. Med. Hypotheses 33 (1990) 69-71
78. Santos J.L., Grandal M., Fontanellas A., Moran M.J., and Enriquez de Salamanca R. Prevalencia de porfiria cutanea tarda en Madrid y asociacion entre la porfirinuria y el consumo de etanol en un modelo de regresion lineal multiple. Med. Clin. (Barc). 107 (1996) 614-616
79. Chang K.J., Lu F.J., Tung T.C., and Lee T.P. Studies on patients with polychlorinated biphenyl poisoning. 2. Determination of urinary coproporphyrin, uroporphyrin, delta-aminolevulinic acid and porphobilinogen. Res. Commun. Chem. Pathol. Pharmacol. 30 (1980) 547-554
80. Colombi A., Maroni M., and Ferioli A. Increase in urinary porphyrin excretion in workers exposed to polychlorinated biphenyls. J. Appl. Toxicol. 2 (1982) 117-121
81. Nonaka S., Shimoyama T., Honda T., and Yoshida H. Analysis of urinary porphyrins in polychlorinated biphenyl poisoning (Yusho) patients. In: Strik J.J.T.W.A., and Koeman J.H. (Eds). Chemical Porphyria in Man (1979), Elsevier, North Holland, Amsterdam 69-73
82. Osterloh J., Cone J., Harrison R., Wade R., and Becker C. Pilot survey of urinary porphyrins from persons transiently exposed to a PCB transformer fire. J. Toxicol. Clin. Toxicol. 24 (1986) 533-544
83. Pazderova-Vejlupkova J., Lukas E., Nemcova M., Pickova J., and Jirasek L. The development and prognosis of chronic intoxication by tetrachlordibenzo-p-dioxin in men. Arch. Environ. Health 36 (1981) 5-11
84. Seki Y., Kawanishi S., and Sano S. Mechanism of PCB-induced porphyria and Yusho disease. Ann. N. Y. Acad. Sci. 514 (1987) 222-234
85. Strik J.J. Porphyrins in urine as an indication of exposure to chlorinated hydrocarbons. Ann. N. Y. Acad. Sci. 320 (1979) 308-310
86. Calvert G.M., Sweeney M.H., Fingerhut M.A., Hornung R.W., and Halperin W.E. Evaluation of porphyria cutanea tarda in U.S. workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Am. J. Ind. Med. 25 (1994) 559-571
87. Boyd A.S., Neldner K.H., and Naylor M. 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced porphyria cutanea tarda among pediatric patients. J. Am. Acad. Dermatol. 21 (1989) 1320-1321
88. Jones R.E., and Chelsky M. Further discussion concerning porphyria cutanea tarda and TCDD exposure. Arch. Environ. Health 41 (1986) 100-103
89. Bleiberg J., Wallen M., Brodkin R., and Applebaum I.L. Industrially-acquired porphyria. Arch. Derm. (Chic.) 89 (1964) 793-797
90. Jirasek L., Kalensky J., Kubec K., Pazderova J., and Lukas E. [Acne chlorina, porphyria cutanea tarda and other manifestations of general poisoning during the manufacture of herbicides. II]. Cesk. Dermatol. 49 (1974) 145-157
91. Jirasek L., Kalensky J., Kubec K., Pazderova J., and Lukas E. [Chloracne, porphyria cutanea tarda, and other poisonings due to the herbicides]. Hautarzt 27 (1976) 328-333
92. McConnell R., Anderson K., Russell W., Anderson K.E., Clapp R., Silbergeld E., and Landrigan P. Angiosarcoma, porphyria cutnea tarda, and probable chloracne in a worker exposed to waste oil contaminated with 2,3,7.,8-tetrachlorodibenzeo-p-dioxin. Br. J. Ind. Med. 50 (2000) 699-703
93. Caputo R., Monti M., Ermacora E., Carminati G., Gelmetti C., Gianotti R., Gianni E., and Puccinelli V. Cutaneous manifestations of tetrachlorodibenzo-p-dioxin in children and adolescents. Follow-up 10 years after the Seveso, Italy, accident. J. Am. Acad. Dermatol. 19 (1988) 812-819
94. De Matteis F., Prior B.E., and Rimington C. Nervous and biochemical disturbances following hexachlorobenzene intoxication. Nature 191 (1961) 363-366
95. Gajdos A., and Gajdos-Török M. The therapeutic effect of adenosine-5-monophosphoric acid in porphyria. Lancet 2 (1961) 175-177
96. Kantemir I. Porphyrin kimyasi re analiz metodlari. Turk. J. Tecr. Biyol. Derg. 20 (1960) 1
97. Ockner R.K., and Schmid R. Acquired porphyria in man and rat due to hexachlorobenzene intoxication. Nature 189 (1961) 499
98. Carpenter H.M., Williams D.E., and Buhler D.R. Hexachlorobenzene-induced porphyria in Japanese quail: Changes in microsomal enzymes. J. Toxicol. Environ. Health 15 (1985) 431-444
99. Carpenter H.M., Williams D.E., Henderson M.C., Bender R.C., and Buhler D.R. Hexachlorobenzene-induced porphyria in Japanese quail. Effect of pretreatment with phenobarbital or beta-naphthoflavone. Biochem. Pharmacol. 33 (1984) 3875-3881
100. Strik J.J. Chemical porphyria in Japanese quail (Coturnix c. Japonica). Enzyme 16 (1973) 211-223
101. Strik J.J. Species differences in experimental porphyria caused by polyhalogenated aromatic compounds. Enzyme 16 (1973) 224-230
102. Strik J.J.T.W.A., and Wit J.G. Hepatic porphyria in birds and mammals. TNO-nieuws 27 (1972) 604-610
103. Vos J.G., Strik J.J., van Holsteyn C.W., and Pennings J.H. Polychlorinated biphenyls as inducers of hepatic porphyria in Japanese quail, with special reference to -aminolevulinic acid synthetase activity, fluorescence, and residues in the liver. Toxicol. Appl. Pharmacol. 20 (1971) 232-240
104. Carlson G.P. Brominated benzene induction of hepatic porphyria. Experientia 35 (1978) 513-514
105. Koss G., Seubert S., Seubert A., Seidel J., Koransky W., and Ippen H. Studies on the toxicology of hexachlorobenzene. V. Different phases of porphyria during and after treatment. Arch. Toxicol. 52 (1983) 13-22
106. Smith A.G., and Francis J.E. Relative abilities on a molar basis of hexafluoro-, hexachloro- and hexabromobenzenes to decrease liver uroporphyrinogen decarboxylase activity and cause porphyria in female rats. Res. Commun. Chem. Pathol. Pharmacol. 28 (1980) 377-384
107. Smith A.G., Francis J.E., and Bird I. Distinction between octachlorostyrene and hexachlorobenzene in their potentials to induce ethoxyphenoxazone deethylase and cause porphyria in rats and mice. J. Biochem. Toxicol. 1 (1986) 105-117
108. Strik J.J.T.W.A., and Wit J.G. Porphyrogenic action of hexachlorbenzene and octachlorostyrene. In: Doss M. (Ed). Porphyrins in Human Disease, Karker, Basel (1976) 418-423
109. IPCS. Hexachlorobenzene (1997), WHO, Geneva
110. Stewart F.P., and Smith A.G. Metabolism of the "mixed" cytochrome P-450 inducer hexachlorobenzene by rat liver microsomes. Biochem. Pharmacol. 35 (1986) 2163-2170
111. Grant D.L., Shields J.B., and Villeneuve D.C. Chemical (HCB) porphyria: Effect of removal of sex organs in the rat. Bull. Environ. Contam. Toxicol. 14 (1975) 422-425
112. San Martin de Viale L.C., Viale A.A., Nacht S., and Grinstein M. Experimental porphyria induced in rats by hexachlorobenzene. A study of the porphyrins excreted by urine. Clin. Chim. Acta 28 (1970) 13-23
113. Smith A.G., Francis J.E., Dinsdale D., Manson M.M., and Cabral J.R. Hepatocarcinogenicity of hexachlorobenzene in rats and the sex difference in hepatic iron status and development of porphyria. Carcinogenesis 6 (1985) 631-636
114. Smith A.G., and Francis J.E. Increased inhibition of hepatic uroporphyrinogen decarboxylase by hexachlorobenzene in male rats given the oestrogenic drugs diethylstilboestrol and chlorotrianisene. Biochem. Pharmacol. 30 (1981) 1849-1853
115. Goldstein J.A., Hickman P., Burse V.W., and Bergman H. A comparative study of two polychlorinated biphenyl mixtures (Aroclors 1242 and 1016) containing 42% chlorine on induction of hepatic porphyria and drug metabolizing enzymes. Toxicol. Appl. Pharmacol. 32 (1975) 461-473
116. Hill R.H. Effects of polyhalogenated aromatic compounds on porphyria metabolism. Environ. Health Perspect. 60 (1985) 139-145
117. Honda T., Nonaka S., Murayama F., Ohgami T., Shimoyama T., and Yoshida H. Effects of KC-400 (polychlorinated biphenyls) on porphyrin metabolism-liver and blood porphyrin analyses in rats treated with KC-400. J. Dermatol. 10 (1983) 259-265
118. Koss G., Meyer-Rogge D., Seubert S., Seubert A., and Losekam M. 2,2′,3′,4,4′5,5′-Hepatachlorobiphenyl (PCB 180)-on its toxicokinetics, biotransformation and porphyrinogenic action in female rats. Arch. Toxicol. 67 (1993) 651-654
119. Sano S., Kawanishi S., and Seki Y. Toxicity of polychlorinated biphenyl with special reference to porphyrin metabolism. Environ. Health Perspect. 59 (1985) 137-143
120. Gupta B.N., McConnell E.E., Goldstein J.A., Harris M.W., and Moore J.A. Effects of a polybrominated biphenyl mixture in the rat and mouse. I. Six-month exposure. Toxicol. Appl. Pharmacol. 68 (1983) 1-18
121. Smith A.G., Francis J.E., Green J.A., Greig J.B., Wolf C.R., and Manson M.M. Sex-linked hepatic uroporphyria and the induction of cytochromes P450IA in rats caused by hexachlorobenzene and polyhalogenated biphenyls. Biochem. Pharmacol. 40 (1990) 2059-2068
122. Goldstein J.A., Hickman P., Bergman H., and Vos J.G. Hepatic porphyria induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the mouse. Res. Commun. Chem. Pathol. Pharmacol. 6 (1973) 919-928
123. Smith A.G., Francis J.E., Kay S.J., and Greig J.B. Hepatic toxicity and uroporphyrinogen decarboxylase activity following a single dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin to mice. Biochem. Pharmacol. 30 (1981) 2825-2830
124. Sweeney G.D., Jones K.G., Cole F.M., Basford D., and Krestynski F. Iron deficiency prevents liver toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Science 204 (1979) 332-335
125. Cantoni L., Salmona M., and Rizzardini M. Porphyrogenic effect of chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin in female rats. Dose-effect relationship following urinary excretion of porphyrins. Toxicol. Appl. Pharmacol. 57 (1981) 156-163
126. Goldstein J.A., Linko P., and Bergman H. Induction of porphyria in the rat by chronic versus acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Pharmacol. 31 (1982) 1607-1613
127. Jones K.G., and Sweeney G.D. Dependence of the porphyrogenic effect of 2,3,7,8-tetrachlorodibenzo(p)dioxin upon inheritance of aryl hydrocarbon hydroxylase responsiveness. Toxicol. Appl. Pharmacol. 53 (1980) 42-49
128. Robinson S.W., Clothier B., Akhtar R.A., Yang A.L., Latour I., Van Ijperen C., Festing M.F., and Smith A.G. Non-Ahr gene susceptibility loci for porphyria and liver injury induced by the interaction of "dioxin" with iron overload in mice. Mol. Pharmacol. 61 (2002) 674-681
129. Davies R., Clothier B., Robinson S.W., Edwards R.E., Greaves P., Luo J., Gant T.W., Chernova T., and Smith A.G. Essential role of the AH receptor in the dysfunction of heme metabolism induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Chem. Res. Toxicol. 21 (2008) 330-340
130. Greig J.B., Francis J.E., Kay S.J., Lovell D.P., and Smith A.G. Incomplete correlation of 2,3,7,8-tetrachlorodibenzo-p-dioxin hepatotoxicity with Ah phenotype in mice. Toxicol. Appl. Pharmacol. 74 (1984) 17-25
131. Linko P., Yeowell H.N., Gasiewicz T.A., and Goldstein J.A. Induction of cytochrome P-450 isozymes by hexachlorobenzene in rats and aromatic hydrocarbon (Ah)-responsive mice. J. Biochem. Toxicol. 1 (1986) 95-107
132. Hahn M.E., Gasiewicz T.A., Linko P., and Goldstein J.A. The role of the Ah locus in hexachlorobenzene-induced porphyria. Studies in congenic C57BL/6J mice. Biochem. J. 254 (1988) 245-254
133. Hahn M.E., Goldstein J.A., Linko P., and Gasiewicz T.A. Interaction of hexachlorobenzene with the receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in vitro and in vivo. Evidence that hexachlorobenzene is a weak Ah receptor agonist. Arch. Biochem. Biophys. 270 (1989) 344-355
134. Akhtar R., and Smith A.G. Chromosomal linkage analysis of porphyria in mice induced by hexachlorobenzene-iron synergism: A model of sporadic porphyria cutanea tarda. Pharmacogenetics 8 (1998) 485-494
135. Smith A.G., and Francis J.E. Synergism of iron and hexachlorobenzene inhibits hepatic uroporphyrinogen decarboxylase in inbred mice. Biochem. J. 214 (1983) 909-913
136. Goldstein J.A., Friesen M., Scotti T.M., Hickman P., Hass J.R., and Bergman H. Assessment of the contribution of chlorinated dibenzo-p-dioxins and dibenzofurans to hexachlorobenzene-induced toxicity, porphyria, changes in mixed function oxygenases, and histopathological changes. Toxicol. Appl. Pharmacol. 46 (1978) 633-649
137. Van den Berg M., Birnbaum L.S., Denison M., De Vito M., Farland W., Feeley M., Fiedler H., Hakansson H., Hanberg A., Haws L., Rose M., Safe S., et al. The 2005 World Health Organization reevaluation of human and mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol. Sci. 93 (2006) 223-241
138. Alleman M.A., Koster J.F., Wilson J.H., Edixhoven-Bosdijk A., Slee R.G., Kroos M.J., and von Eijk H.G. The involvement of iron and lipid peroxidation in the pathogenesis of HCB induced porphyria. Biochem. Pharmacol. 34 (1985) 161-166
139. Bach P.H., Taljaard J.J.F., Jouubert S.M., and Shanley B.C. The effect of iron overload on the development of hexachlorobenzene (HCB) porphyria. S. Afr. J. Lab. Clin. Med. 17 (1971) 75-76
140. Smith A.G., Carthew P., Francis J.E., Cabral J.R., and Manson M.M. Enhancement by iron of hepatic neoplasia in rats caused by hexachlorobenzene. Carcinogenesis 14 (1993) 1381-1387
141. Taljaard J.J., Shanley B.C., Deppe W.M., and Joubert S.M. Porphyrin metabolism in experimental hepatic siderosis in the rat. 2. Combined effect of iron overload and hexachlorobenzene. Br. J. Haemotol. 23 (1972) 513-519
142. Taljaard J.J., Shanley B.C., Deppe W.M., and Joubert S.M. Porphyrin metabolism in experimental hepatic siderosis in the rat. 3. Effect of iron overload and hexachlorobenzene on liver haem biosynthesis. Br. J. Haematol. 23 (1972) 587-593
143. Blekkenhorst G., Day R.S., and Eales L. The effect of bleeding and iron administration on the development of hexachlorobenzene-induced rat porphyria. Int. J. Biochem. 12 (1980) 1013-1017
144. Wainstok de Calmanovici R., Billi S.C., Aldonatti C.A., and San Martin de Viale L.C. Effect of desferrioxamine on the development of hexachlorobenzene induced porphyria. Biochem. Pharmacol. 35 (1986) 2399-2405
145. Gorman N., Zaharia A., Trask H.S., Szakacs J.G., Jacobs N.J., Jacobs J.M., Balestra D., Sinclair J.F., and Sinclair P.R. Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology 46 (2007) 1927-1934
146. Jones K.G., Cole F.M., and Sweeney G.D. The role of iron in the toxicity of 2,3,7,8-tetrachlorodibenzo-(p)-dioxin (TCDD). Toxicol. Appl. Pharmacol. 61 (1981) 74-88
147. Franklin M.R., Phillips J.D., and Kushner J.P. Attenuation of polychlorinated biphenyl induced uroporphyria by iron deprivation. Environ. Toxicol. Pharmacol. 20 (2005) 417-423
148. Smith A., Cabral J.R.P., Carthew P., Francis J., and Manson M.M. Carcinogenicity of iron in conjunction with a chlorinated environmental chemical, hexachlorobenzene, in C57BL/10scsn mice. Int. J. Cancer 43 (1989) 492-496
149. Smith A.G., Clothier B., Robinson S., Scullion M.J., Carthew P., Edwards R., Luo J., Lim C.K., and Toledano M. Interaction between iron metabolism and 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice with variants of the Ahr gene: A hepatic oxidative mechanism. Mol. Pharmacol. 53 (1998) 52-61
150. Siersema P., van Helvoirt R.P., Ketelaars G.M.M., Cleton-shoeteman M.I., Debruin W.C., Vanijk H., and Wilson J.H.P. Colocalization of iron and uroporphyrin in hepatocytes of mice with hexachlorobenzene-induced porphyria. Hepatology 12 (1990) 446 446
151. Khanna R.N., and Smith A.G. Fate of hexachlorobenzene in C57BL/10 mice with iron overload. Biochem. Pharmacol. 34 (1985) 4157-4162
152. Smith A.G., Francis J.E., Kay S.J., Greig J.B., and Stewart F.P. Mechanistic studies of the inhibition of hepatic uroporphyrinogen decarboxylase in C57BL/10 mice by iron-hexachlorobenzene synergism. Biochem. J. 238 (1986) 871-878
153. Francis J.E., and Smith A.G. Polycyclic aromatic hydrocarbons cause hepatic porphyria in iron-loaded C57BL/10 mice: Comparison of uroporphyrinogen decarboxylase inhibition with induction of alkoxyphenoxazone dealkylations. Biochem. Biophys. Res. Commun. 146 (1987) 13-20
154. Urquhart A.J., Elder G.H., Roberts A.G., Lambrecht R.W., Sinclair P.R., Bement W.J., Gorman N., and Sinclair J.A. Uroporphyria produced in mice by 20-methylcholanthrene and 5-aminolaevulinic acid. Biochem. J. 253 (1988) 357-362
155. Smith A.G., Francis J.E., and Carthew P. Iron as a synergist for hepatocellular carcinoma induced by polychlorinated biphenyls in Ah-responsive C57BL/10scsn mice. Carcinogenesis 11 (1990) 437-444
156. Smith A.G., and Francis J.E. Genetic variation of iron-induced uroporphyria in mice. Biochem. J. 291 (1993) 29-35
157. Deam S., and Elder G.H. Uroporphyria produced in mice by iron and 5-aminolevulinic acid. Biochem. Pharmacol. 41 (1991) 2019-2022
158. Constantin D., Francis J.E., Akhtar R.A., Clothier B., and Smith A.G. Uroporphyria induced by 5-aminolaevulinic acid alone in Ahrd SWR mice. Biochem. Pharmacol. 52 (1996) 1407-1413
159. Phillips J.D., Jackson L.K., Bunting M., Franklin M.R., Thomas K.R., Levy J.E., Andrews N.C., and Kushner J.P. A mouse model of familial porphyria cutanea tarda. Proc. Natl. Acad. Sci. USA 98 (2001) 259-264
160. Sinclair P.R., Gorman N., Walton H.S., Bement W.J., Sinclair J.F., Gerhard G.S., Szakacs J.G., Andrews N.C., and Levy J.E. Uroporphyria in Hfe mutant mice given 5-aminolevulinate: a new model of Fe-mediated porphyria cutanea tarda. Hepatology 33 (2001) 406-412
161. (-/-) mice. Hepatology 40 (2004) 942-950
162. (-/-) mice as a model for porphyria cutanea tarda. Hepatology 37 (2003) 351-358
163. Rios De Molina M.C., Mazzetti M.B., Galigniana M., Aldonatti C., Tomio J.M., and San Martin De Viale L.C. The decrease in uroporphyrinogen decarboxylase activity induced by ethanol predisposes rats to the development of porphyria and accelerates xenobiotic-triggered porphyria, regardless of hepatic damage. Braz. J. Med. Biol. Res. 35 (2002) 1273-1283
164. de Verneuil H., Nordmann Y., Phung N., Grandchamp B., Aitken G., Grelier M., and Noire J. Familial and sporadic porphyria cutanea: Two different diseases. Int. J. Biochem. 9 (1978) 927-931
165. Smith A.G., Cabral J.R., and De Matteis F. A difference between two strains of rats in their liver non-haem iron content and in their response to the porphyrogenic effect of hexachlorobenzene. Chem. Biol. Interact. 27 (1979) 353-363
166. Greig J.B., Francis J.E., and Smith A.G. Genetic control of the hepatotoxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice. Organohalogen Compd. 1 (1990) 177-180
167. Greig J.B., Francis J.E., Kay S.J., Lister T., Ray D.E., Seawright A.A., and Smith A.G. Pleiotropic effect of the gene hairless on hepatotoxicity of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in mice. Arch. Toxicol. 60 (1987) 350-354
168. Sen S., Satagopan J.M., Broman K.W., and Churchill G.A. R/qtldesign: Inbred line cross experimental design. Mamm. Genome 18 (2007) 87-93
169. Bensaid M., Fruchon S., Mazeres C., Bahram S., Roth M.P., and Coppin H. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 126 (2004) 1400-1408
170. Elder G.H., Evans J.O., and Matlin S.A. The effect of the porphyrogenic compound, hexachlorobenzene, on the activity of hepatic uroporphyrinogen decarboxylase in the rat. Clin. Sci. Mol. Med. 51 (1976) 71-80
171. Louw M., Neethling A.C., Percy V.A., Carstens M., and Shanley B.C. Effects of hexachlorobenzene feeding and iron overload on enzymes of haem biosynthesis and cytochrome P 450 in rat liver. Clin. Sci. Mol. Med. 53 (1977) 111-115
172. San Martin de Viale L.C., Rios de Molina M.C., Wainstok de Calmanovici R., and Tomio J.M. Porphyrias and porphyrinogen carboxylyase in hexachlorobenzene-induced porphyria. Biochem. J. 168 (1977) 393-400
173. Elder G.H., Lee G.B., and Tovey J.A. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N. Engl. J. Med. 299 (1978) 274-278
174. Elder G.H., and Sheppard D.M. Immunoreactive uroporphyrinogen decarboxylase is unchanged in porphyria caused by TCDD and hexachlorobenzene. Biochem. Biophys. Res. Commun. 109 (1982) 113-120
175. Mylchreest E., and Charbonneau M. Studies on the mechanism of uroporphyrinogen decarboxylase inhibition in hexachlorobenzene-induced porphyria in the female rat. Toxicol. Appl. Pharmacol. 145 (1997) 23-33
176. Wainstok de Calmanovici R., Rios de Molina M.C., Taira de Yamasoto M.C., Tomio J.M., and San Martin de Viale L.C. Mechanism of hexachlorobenzene-induced porphyria in rats. Effect of phenobarbitone pretreatment. Biochem. J. 218 (1984) 753-763
177. Goldstein J.A., Hickman P., and Jue D.L. Experimental hepatic porphyria induced by polychlorinated biphenyls. Toxicol. Appl. Pharmacol. 27 (1974) 437-448
178. Rajamanickam C., Amrutavalli J., Rao M.R., and Padmanaban G. Effect of hexachlorobenzene on haem synthesis. Biochem. J. 129 (1972) 381-387
179. Gorman N., Walton H.S., Bement W.J., Honsinger C.P., Szakacs J.G., Sinclair J.F., and Sinclair P.R. Role of small differences in CYP1A2 in the development of uroporphyria produced by iron and 5-aminolevulinate in C57BL/6 and SWR strains of mice. Biochem. Pharmacol. 58 (1999) 375-382
180. Franklin M.R., Phillips J.D., and Kushner J.P. Accelerated development of uroporphyria in mice heterozygous for a deletion at the uroporphyrinogen decarboxylase locus. J. Biochem. Mol. Toxicol. 15 (2001) 287-293
181. Stonard M.D., Poli G., and De Matteis F. Stimulation of liver heme oxygenase in hexachlorobenzene-induced hepatic porphyria. Arch. Toxicol. 72 (1998) 355-361
182. Carthew P., and Smith A.G. Pathological mechanisms of hepatic tumour formation in rats exposed chronically to dietary hexachlorobenzene. J. Appl. Toxicol. 14 (1994) 447-452
183. Kuiper-Goodman T., Pontefract R.D., and Grant D.L. X-ray(TEM)microanalysis of iron accumulated in liver parenchymal cells of rats with porphyria. Proc. Microsc. Soc. Canada 1 (1974) 14-15
184. Whysner J., and Wang C.X. Hepatocellular iron accumulation and increased cell proliferation in polychlorinated biphenyl-exposed Sprague-Dawley rats and the development of hepatocarcinogenesis. Toxicol. Sci. 62 (2001) 36-45
185. Wahba Z.Z., Murray W.J., and Stohs S.J. Altered hepatic iron distribution and release in rats after exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Bull. Environ. Contam. Toxicol. 45 (1990) 436-445
186. Wahba Z.Z., Murray W.J., and Stohs S.J. Desferrioxamine-induced alterations in hepatic iron distribution, DNA damage and lipid peroxidation in control and 2,3,7.8- tetrachlorodibenzo-p-dioxin-treated rats. J. Appl. Toxicol. 10 (1990) 119-124
187. Rowley B., and Sweeney G.D. Release of ferrous iron from ferritin by liver microsomes: A possible role in the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Can. J. Biochem. Cell Biol. 62 (1984) 1293-1300
188. Tangeras A. Lysosomes, but not mitochondria, accumulate iron and porphyrins in porphyria induced by hexachlorobenzene. Biochem. J. 235 (1986) 671-675
189. Andrews N.C., and Schmidt P.J. Iron homeostasis. Annu. Rev. Physiol. 69 (2007) 69-85
190. Jones K.G., and Sweeney G.D. Association between induction of aryl hydrocarbon hydroxylase and depression of uroporphyrinogen decarboxylase activity. Res. Commun. Chem. Pathol. Pharmacol. 17 (1977) 631-637
191. Jacobs J.M., Sinclair P.R., Sinclair J.F., and Jacobs N.J. Role of inducer binding in cytochrome P-450 IA2-mediated uroporphyrinogen oxidation. J. Biochem. Toxicol. 5 (1990) 193-199
192. Gorman N., Ross K.L., Walton H.S., Bement W.J., Szakacs J.G., Gerhard G.S., Dalton T.P., Nebert D.W., Eisenstein R.S., Sinclair J.F., and Sinclair P.R. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. Hepatology 35 (2002) 912-921
193. (-/-) knockout mouse. Biochem. Biophys. Res. Commun. 331 (2005) 147-152
194. Sinclair P.R., Bement W.J., Lambrecht R.W., Gorman N., and Sinclair J.F. Chlorinated biphenyls induce cytochrome P450IA2 and uroporphyrin accumulation in cultures of mouse hepatocytes. Arch. Biochem. Biophys. 281 (1990) 225-232
195. (-/-) null mutant mice. Biochem. J. 330 (1998) 149-153
196. Sinclair P.R., Gorman N., Walton H.S., Bement W.J., Dalton T.P., Sinclair J.F., Smith A.G., and Nebert D.W. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol. Appl. Pharmacol. 162 (2000) 60-67
197. (-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 173 (2001) 89-98
198. (-/-) male mice: protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol. Appl. Pharmacol. 196 (2004) 410-421
199. van Birgelen A.P., DeVito M.J., Akins J.M., Ross D.G., Diliberto J.J., and Birnbaum L.S. Relative potencies of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls derived from hepatic porphyrin accumulation in mice. Toxicol. Appl. Pharmacol. 138 (1996) 98-109
200. Franklin M.R., Phillips J.D., and Kushner J.P. CYP3A-inducing agents and the attenuation of uroporphyrin accumulation and excretion in a rat model of porphyria cutanea tarda. Biochem. Pharmacol. 60 (2000) 1325-1331
201. de Verneuil H., Sassa S., and Kappas A. Effects of polychlorinated biphenyl compounds, 2,3,7,8-tetrachlorodibenzo-p-dioxin, phenobarbital and iron on hepatic uroporhyrinogen decarboxylase-implications for the pathogenesis of porphyria. Biochem. J. 214 (1983) 145-151
202. Madra S., Mann F., Francis J.E., Manson M.M., and Smith A.G. Modulation by iron of hepatic microsomal and nuclear cytochrome P450, and cytosolic glutathione S-transferase and peroxidase in C57BL/10scsn mice induced with polychlorinated biphenyls (Aroclor 1254). Toxicol. Appl. Pharmacol. 136 (1996) 79-86
203. Faux S.P., Francis J.E., Smith A.G., and Chipman J.K. Induction of 8-hydroxydeoxyguanosine in Ah-responsive mouse liver by iron and Aroclor 1254. Carcinogenesis 13 (1992) 247-250
204. Feldman E.S., and Bacon B.R. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload. Hepatology 9 (1989) 686-692
205. Smith A.G., Francis J.E., Cabral J.R.P., Carthew P., Manson M.M., and Stewart F.P. Iron-enhancement of the hepatic porphyria and cancer induced by polyhalogenated aromatic chemicals. In: Poli G., Cheeseman K.H., Dianzani M.U., and Slater T.F. (Eds). Free Radicals in the Pathogenesis of Liver Injury. Adv. Biosc. 76 (1989), Pergamon Press, Oxford 205-214
206. Stohs S.J. Oxidative stress induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Free Radic. Biol. Med. 9 (1990) 79-90
207. Stohs S.J., Shara M.A., Alsharif N.Z., Wahba Z.Z., and al-Bayati Z.A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced oxidative stress in female rats. Toxicol. Appl. Pharmacol. 106 (1990) 126-135
208. Slezak B.P., Hatch G.E., DeVito M.J., Diliberto J.J., Slade R., Crissman K., Hassoun E., and Birnbaum L.S. Oxidative stress in female B6C3F1 mice following acute and subchronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Sci. 54 (2000) 390-398
209. Brown Jr. J.F., Fish K.M., Mayes B.A., Silkworth J.B., Hamilton S.B., and Whysner J. PCB effects on epigenetic carcinogenic processes. In: Robertson L.W., and Hansen L.G. (Eds). PCBs. Recent Advances in Environmental Toxicology and Health Effects (2001), University Press of Kentucky, Lexington, Kentucky 329-336
210. Gorman N., Zaharia A., Trask H.S., Szakacs J.G., Jacobs N.J., Jacobs J.M., Balestra D., Sinclair J.F., and Sinclair P.R. Effect of iron and ascorbate on uroporphyria in ascorbate-requiring mice as a model for porphyria cutanea tarda. Hepatology 45 (2007) 187-194
211. Horvath M.E., Faux S.P., Smith A.G., Blazovics A., van der Looij M., Feher J., and Cheeseman K.H. Vitamin E protects against iron-hexachlorobenzene induced porphyria and formation of 8-hydroxydeoxyguanosine in the liver of C57BL/10scsn mice. Toxicol. Lett. 122 (2001) 97-102
212. Shertzer H.G., Nebert D.W., Puga A., Ary M., Sonntag D., Dixon K., Robinson L.J., Cianciolo E., and Dalton T.P. Dioxin causes a sustained oxidative stress response in the mouse. Biochem. Biophys. Res. Commun. 253 (1998) 44-48
213. Senft A.P., Dalton T.P., Nebert D.W., Genter M.B., Hutchinson R.J., and Shertzer H.G. Dioxin increases reactive oxygen production in mouse liver mitochondria. Toxicol. Appl. Pharmacol. 178 (2002) 15-21
214. Senft A.P., Dalton T.P., Nebert D.W., Genter M.B., Puga A., Hutchinson R.J., Kerzee J.K., Uno S., and Shertzer H.G. Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. Free Radic. Biol. Med. 33 (2002) 1268-1278
215. Shen D., Dalton T.P., Nebert D.W., and Shertzer H.G. Glutathione redox state regulates mitochondrial reactive oxygen production. J. Biol. Chem. 280 (2005) 25305-25312
216. Shertzer H.G., Genter M.B., Shen D., Nebert D.W., Chen Y., and Dalton T.P. TCDD decreases ATP levels and increases reactive oxygen production through changes in mitochondrial F(0)F(1)-ATP synthase and ubiquinone. Toxicol. Appl. Pharmacol. 217 (2006) 363-374
217. De Matteis F. Role of iron in the hydrogen peroxide-dependent oxidation of hexahydroporphyrins (porphyrinogens): A possible mechanism for the exacerbation by iron of hepatic uroporphyria. Mol. Pharmacol. 33 (1988) 463-469
218. De Matteis F. Porphyria cutanea tarda of the toxic and sporadic varieties. Clin. Dermatol. 16 (1998) 265-275
219. Heikel T., Lockwood W.H., and Rimington C. Formation of non-enzymic heme. Nature 182 (1958) 313
220. Smith A.G., Francis J.E., and De Matteis F. Lobes of rat liver respond at different rates to challenge by dietary hexachlorobenzene. Biochem. Pharmacol. 29 (1980) 3127-3131
221. Seki Y., Kawanishi S., and Sano S. Role of inhibition of uroporphyrinogen decarboxylase in PCB-induced porphyria in mice. Toxicol. Appl. Pharmacol. 90 (1987) 116-125
222. Sinclair P.R., Bement W.J., Bonkovsky H.L., Lambrecht R.W., Frezza J.E., Sinclair J.F., Urquhart A.J., and Elder G.H. Uroporphyrin accumulation produced by halogenated biphenyls in chick-embryo hepatocytes. Reversal of the accumulation by piperonyl butoxide. Biochem. J. 237 (1986) 63-71
223. De Matteis F., Harvey C., Reed C., and Hempenius R. Increased oxidation of uroporphyrinogen by an inducible liver microsomal system. Possible relevance to drug-induced uroporphyria. Biochem. J. 250 (1988) 161-169
224. Jacobs J.M., Sinclair P.R., Bement W.J., Lambrecht R.W., Sinclair J.F., and Goldstein J.A. Oxidation of uroporphyrinogen by methylcholanthrene-induced cytochrome P-450. Essential role of cytochrome P-450d. Biochem. J. 258 (1989) 247-253
225. Lambrecht R.W., Sinclair P.R., Gorman N., and Sinclair J.F. Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450IA2. Arch. Biochem. Biophys. 294 (1992) 504-510
226. Chaufan G., Rios de Molina M.C., and San Martin de Viale L.C. How does hexachlorobenzene treatment affect liver uroporphyrinogen decarboxylase?. Int. J. Biochem. Cell Biol. 33 (2001) 621-630
227. Smith A.G., Francis J.E., and Greig J.B. Continued depression of hepatic uroporphyrinogen decarboxylase activity caused by hexachlorobenzene or 2,3,7,8-tetrachlorodibenzo-p-dioxin despite regeneration after partial hepatectomy. Biochem. Pharmacol. 34 (1985) 1817-1820
228. Elder G.H., Roberts A.G., and Urquhart A.J. Alterations of uroporphyrinogen decarboxylase by chlorinated organics. Ann. N. Y. Acad. Sci. 514 (1987) 141-147
229. Cantoni L., dal Fiume D., Rizzardini M., and Ruggieri R. In vitro inhibitory effect on porphyrinogen carboxylyase of liver extracts from TCDD treated mice. Toxicol. Lett. 20 (1984) 211-217
230. Rios de Molina M.C., Wainstok de Calmanovici R., and San Martin de Viale L.C. Investigations on the presence of porphyrinogen carboxy-lyase inhibitor in the liver of rats intoxicated with hexachlorobenzene. Int. J. Biochem. 12 (1980) 1027-1032
231. Smith A.G., and Francis J.E. Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload. Biochem. J. 246 (1987) 221-226
232. Francis J.E., and Smith A.G. Oxidation of uroporphyrinogens by hydroxyl radicals. Evidence for nonporphyrin products as potential inhibitors of uroporphyrinogen decarboxylase. FEBS Lett. 233 (1988) 311-314
233. Lambrecht R.W., Jacobs J.M., Sinclair P.R., and Sinclair J.F. Inhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P-450-mediated uroporphyrinogen oxidation. Biochem. J. 269 (1990) 437-441
234. Phillips J.D., Bergonia H.A., Reilly C.A., Franklin M.R., and Kushner J.P. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc. Natl. Acad. Sci. USA 104 (2007) 5079-5084
235. Danton M., and Lim C.K. Porphomethene inhibitor of uroporphyrinogen decarboxylase: Analysis by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomed. Chromatogr. 21 (2007) 661-663
236. Mauzerall D., and Granick S. Porphyrin biosynthesis in erythrocytes. 3. Uroporphyrinogen and its decarboxylase. J. Biol. Chem. 232 (1958) 1141-1162
237. Sinclair P.R., Gorman N., Walton H.S., Bement W.J., Jacobs J.M., and Sinclair J.F. Ascorbic acid inhibition of cytochrome P450-catalyzed uroporphyrin accumulation. Arch. Biochem. Biophys. 304 (1993) 464-470
238. Sinclair P.R., Gorman N., Sinclair J.F., Walton H.S., Bement W.J., and Lambrecht R.W. Ascorbic acid inhibits chemically induced uroporphyria in ascorbate-requiring rats. Hepatology 22 (1995) 565-572
239. Lin W., and Timkovich R. Oxygenated tetrapyrroles produced from porphyrinogens. Bioorg. Chem. 22 (1994) 72-94
240. Guo R., Lim C.K., and De Matteis F. Peroxylated and hydroxylated uroporphyrins: a study of their production in vitro in enzymic and chemical model systems. Biomed. Chromatogr. 10 (1996) 213-220
241. Luo J., and Lim C.K. Isolation and characterization of new porphyrin metabolites in human porphyria cutanea tarda and in rats treated with hexachlorobenzene by HPTLC, HPLC and liquid secondary ion mass spectrometry. Biomed. Chromatogr. 9 (1995) 113-122
242. Lim C.K., Danton M., Clothier B., and Smith A.G. Dihydroxy-, hydroxyspirolactone-, and dihydroxyspirolactone-urochlorins induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in the liver of mice. Chem. Res. Toxicol. 19 (2006) 1660-1667
243. Okey A.B. An aryl hydrocarbon receptor odyssey to the shores of toxicology: the Deichmann Lecture, International Congress of Toxicology-XI. Toxicol. Sci. 98 (2007) 5-38
244. Kociba R.J., Keyes D.G., Beyer J.E., Carreon R.M., Wade C.E., Dittenber D.A., Kalnins R.P., Frauson L.E., Park C.N., Barnard S.D., Hummel R.A., and Humiston C.G. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 46 (1978) 279-303
245. Siersema P.D., Cleton-Soeteman M.I., de Bruijn W.C., ten Kate F.J., van Eijk H.G., and Wilson J.H. Ferritin accumulation and uroporphyrin crystal formation in hepatocytes of C57BL/10 mice: A time-course study. Cell Tissue Res. 274 (1993) 405-412
246. Mayes B.A., McConnell E.E., Neal B.H., Brunner M.J., Hamilton S.B., Sullivan T.M., Peters A.C., Ryan M.J., Toft J.D., Singer A.W., Brown Jr. J.F., Menton R.G., et al. Comparative carcinogenicity in Sprague-Dawley rats of the polychlorinated biphenyl mixtures Aroclors 1016, 1242, 1254, and 1260. Toxicol. Sci. 41 (1998) 62-76
247. Stewart F.P., Manson M.M., Cabral J.R., and Smith A.G. Hexachlorobenzene as a promoter of diethylnitrosamine-initiated hepatocarcinogenesis in rats and comparison with induction of porphyria. Carcinogenesis 10 (1989) 1225-1230
248. Fracanzani A.L., Taioli E., Sampietro M., Fatta E., Bertelli C., Fiorelli G., and Fargion S. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J. Hepatol. 35 (2001) 498-503
249. Linet M., Gridley G., Nyren O., Mellemkjaer L., Olsen J., Keehn S., Adami H., and Fraumeni J. Primary liver cancer, other malignancies, and mortality risks following porphyria: A cohort study in Denmark and Sweden. Am. J. Epidemiol. 149 (1999) 1010-1015
250. Salata H., Cortes J.M., Enriquez de Salamanca R., Oliva H., Castro A., Kusak E., Carreno V., and Hernandez Guio C. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J. Hepatol. 1 (1985) 477-487
251. Smith A.G., Carthew P., Francis J.E., and Ingebrigtsen K. Influence of iron on the induction of hepatic tumors and porphyria by octachlorostyrene in C57BL/10scsn mice. Cancer Lett. 81 (1994) 145-150
252. Madra S., Styles J., and Smith A.G. Perturbation of hepatocyte nuclear populations induced by iron and polychlorinated biphenyls in C57BL/10scsn mice during carcinogenesis. Carcinogenesis 16 (1995) 719-727
253. Rumsby P.C., Evans J.G., Phillimore H.E., Carthew P., and Smith A.G. Search for Ha-ras codon 61 mutations in liver tumours caused by hexachlorobenzene and Aroclor 1254 in C57BL/10scsn mice with iron overload. Carcinogenesis 13 (1992) 1917-1920
254. Davies R., Clothier B., and Smith A.G. Mutation frequency in the laci gene of liver DNA from lambda/laci transgenic mice following the interaction of PCBs with iron causing hepatic cancer and porphyria. Mutagenesis 15 (2000) 379-383
255. Libbrecht L., Meerman L., Kuipers F., Roskams T., Desmet V., and Jansen P. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J. Pathol. 199 (2003) 191-200
256. Knasmuller S., Parzefall W., Helma C., Kassie F., Ecker S., and Schulte-Hermann R. Toxic effects of griseofulvin: Disease models, mechanisms, and risk assessment. Crit. Rev. Toxicol. 27 (1997) 495-537
257. Thierbach R., Schulz T.J., Isken F., Voigt A., Mietzner B., Drewes G., von Kleist-Retzow J.C., Wiesner R.J., Magnuson M.A., Puccio H., Pfeiffer A.F., Steinberg P., et al. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum. Mol. Genet. 14 (2005) 3857-3864
258. Bulaj Z.J., Franklin M.R., Phillips J.D., Miller K.L., Bergonia H.A., Ajioka R.S., Griffen L.M., Guinee D.J., Edwards C.Q., and Kushner J.P. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J. Lab. Clin. Med. 136 (2000) 482-488
259. Sinclair P.R., Gorman N., Tsyrlov I.B., Fuhr U., Walton H.S., and Sinclair J.F. Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metab. Dispos. 26 (1998) 1019-1025
260. Danton M., and Lim C.K. High-performance liquid chromatography/electrospray ionization tandem mass spectrometry of hydroxylated uroporphyrin and urochlorin derivatives formed by photochemical oxidation of uroporphyrinogen I. Biomed. Chromatogr. 21 (2007) 534-545